Literature DB >> 9642739

[Progress in the control of world blindness and future perspectives].

B Thylefors1, S Resnikoff.   

Abstract

Worldwide, there are approximately 180 million severely visually impaired people, of whom some 45 million are blind. Cataract remains the major cause of blindness, especially in the less developed countries. Substantial improvements have been achieved in the control of blinding diseases, mainly in respect of onchocerciasis and xerophthalmia. More recently, a WHO alliance for the eradicating of trachoma by the year 2020 has been set up. In Africa, the situation remains critical in spite of significant improvements in the training of eye care personnel and the implementation of new eye care facilities. If no additional action is taken, the number of blind from cataract will steadily increase, mainly because of population growth and aging. Substantial further efforts should be made to make appropriate eye care accessible and affordable to all those in need.

Entities:  

Mesh:

Year:  1998        PMID: 9642739

Source DB:  PubMed          Journal:  Sante        ISSN: 1157-5999


  4 in total

1.  Low-dose transscleral diode laser cyclophotocoagulation (TSCPC) as a potential single treatment for primary open-angle glaucoma (POAG) in Malawi?

Authors:  Markus Schulze Schwering; Petros Kayange; Volker Klauss; Khumbo Kalua; Martin S Spitzer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-08-21       Impact factor: 3.117

2.  Incidence of visual loss in rural southwest Uganda.

Authors:  S M Mbulaiteye; B C Reeves; F Mulwanyi; J A G Whitworth; G Johnson
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

3.  An Imaging Review of Intra-ocular Calcifications.

Authors:  Sushil G Kachewar; Devidas S Kulkarni
Journal:  J Clin Diagn Res       Date:  2014-01-12

4.  Ultrasonographic findings in patients examined in cataract detection-and-treatment campaigns: a retrospective study.

Authors:  Marcio Henrique Mendes; Alberto Jorge Betinjane; Adhele de Sá Cavalcante; Cheng Te Cheng; Newton Kara-José
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.